Jun Qian

Publications (71)98.32 Total impact

• Article: Overexpression of miR-378 is frequent and may affect treatment outcomes in patients with acute myeloid leukemia.

  Jun Qian, Jiang Lin, Wei Qian, Ji-Chun Ma, Si-Xuan Qian, Yun Li, Jing Yang, Jian-Yong Li, Cui-Zhu Wang, Hai-Yan Chai, Xing-Xing Chen, Zhao-Qun Deng
  [show abstract] [hide abstract]
  ABSTRACT: MicroRNA miR-378 plays important roles in tumorigenesis by enhancing cell survival, reducing apoptosis, promoting tumor growth, angiogenesis and promoting cell migration and invasion. Abnormal expression of miR-378 has been observed in various types of cancers. The aim of this study was to investigate the expression status of miR-378 and its clinical significance in patients with acute myeloid leukemia (AML) using real-time quantitative PCR. miR-378 overexpression was identified in 26 of 84 (31%) AML patients. The patients with miR-378 overexpression had lower hemoglobin level than those without miR-378 overexpression (66 versus 78g/L, respectively, P=0.010). The frequency of miR-378 overexpression in FAB-M2 subtype was higher than other subtypes (44% versus 20%, P=0.032). Moreover, the frequency of miR-378 overexpression was higher in patients with t(8;21) than in others (64% versus 24%, P=0.012). The status of miR-378 expression was not correlated with the mutations of eight genes (FLT3-ITD, NPM1, C-KIT, IDH1/IDH2, DNMT3A, C/EBPA and U2AF1). The difference in relapse-free survival was observed between patients with and without miR-378 overexpression (P=0.049). These findings suggest that miR-378 up-regulation is a common event and might have an adverse impact on prognosis in AML.
  Leukemia research 04/2013; · 2.36 Impact Factor
• Article: The Methylation Status of the DDX43 Promoter in Chinese Patients with Chronic Myeloid Leukemia.

  Qin Chen, Jiang Lin, Jun Qian, Zhao-Qun Deng, Wei Qian, Jing Yang, Yun Li, Xing-Xing Chen, Yu-Juan Ma, Ji-Chun Ma, Qing Liu
  [show abstract] [hide abstract]
  ABSTRACT: Aberrant DNA methylation is a common epigenetic alteration and an important feature in human cancers. The DEAD box polypeptide 43 (DDX43) has been found to be overexpressed in various solid tumors and some hematologic malignancies. In the present study, we investigated the methylation status of the DDX43 promoter in 87 Chinese patients with chronic myeloid leukemia (CML) using real-time quantitative methylation-specific polymerase chain reaction and examined the DDX43 transcript in 35 patients using real-time quantitative polymerase chain reaction. DDX43 promoter hypomethylation was observed in 22 (25.3%) CML patients. No significant correlation was found between the hypomethylation of the DDX43 promoter with the age, sex, white blood cell counts, hemoglobin concentration, platelet counts, and chromosomal abnormalities of CML patients (p>0.05). The frequency of DDX43 hypomethylation in patients in the chronic phase, in the accelerated phase, and in blast crisis was 23.4% (15/64), 25.0% (2/8), and 33.3% (5/15), respectively (p>0.05). There was a significant correlation between DDX43 hypomethylation and DDX43 transcript (r=0.469, p=0.004). Our data suggest that hypomethylation of the DDX43 promoter may be an early and frequent molecular event in the development of CML in Chinese patients.
  Genetic Testing and Molecular Biomarkers 03/2013; · 1.11 Impact Factor
• Article: [Expression of SALL4 Gene in Patients with Acute and Chronic Myeloid Leukemia].

  Qin Chen, Jun Qian, Jiang Lin, Jing Yang, Yun Li, Cui-Zhu Wang, Hai-Yan Chai, Xing-Xing Chen, Zhen Qian, Ji-Chun Ma, Ming Zhang
  [show abstract] [hide abstract]
  ABSTRACT: The aim of this study was to investigate the expression level of the SALL4 gene and its clinical significance in patients with acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Real-time quantitative PCR (RQ-PCR) was performed to detect the expression level of SALL4 mRNA in bone marrow mononuclear cells (BMMNC) from 35 AML, 12 CML patients and 24 iron deficiency anemia patients as controls. The results indicated that the expression level of SALL4 in AML (0%-14%, median 1.43%) was obviously higher than that in controls (0% - 1%, median 0%) (P < 0.001). SALL4 expression was positive in 65.7% (23/35) AML patients. The frequency of SALL4 expression was in M2 (86.7%, 13/15) > M3 (75.0%, 6/8) > M1 (60.0%, 3/5) > M4 (14.3%, 1/7), and the difference among 4 groups was statistically significant (P = 0.008); there was no correlation of the frequency of SALL4 expression with the age, sex, white blood cell WBC count, hemoglobin concentration, platelet count and chromosomal abnormalities of AML patients (P > 0.05). All the 13 CML cases showed positive expression of SALL4 gene (1% - 128%, median 19.39%), which was higher than that in controls (P < 0.001). The analysis of receiver operating characteristic (ROC) curve showed the area under ROC curve (AUC) of AML and CML were 0.983 (95% confidence interval: 0.95 - 1.017) and 0.997 (95% confidence interval: 0.986 - 1.007) respectively. It is concluded that SALL4 expression is a common molecular event and can be considered as a molecular marker for assisting diagnosis of AML and CML.
  Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology 03/2013; 21(2):315-9.
• Article: Development of a High-Resolution Melting Analysis for the Detection of the SF3B1 Mutations.

  Jing Yang, Jun Qian, Jiang Lin, Xiao-Fei Yang, Wei Qian, Qin Chen, Dong-Ming Yao, Cui-Zhu Wang, Xing-Xing Chen, Gao-Fei Xiao, Yu-Juan Ma
  [show abstract] [hide abstract]
  ABSTRACT: SF3B1, located on chromosome 2q33.1, encodes a core component of RNA-splicing machinery, and its mutation has been described in myelodysplastic syndromes (MDS) characterized with ring sideroblasts (RS). To explore the reliability and sensitivity of the high-resolution melting analysis (HRMA) technique for the identification of the SF3B1 mutations, mutations in 92 patients with MDS were detected in this study. The sensitivity could reach 5%, obviously higher than the 25% of direct DNA sequencing. A low frequency (5.4%) of SF3B1 mutations were identified in patients with MDS, including three cases of K700E, one case of H662Q, and one case of K666M. Further, SF3B1 mutations were more frequently recurrent in the 33% of patients with MDS characterized with RS, whereas in other subtypes of MDS, only 2.3% of patients were detected with SF3B1 mutations (p=0.006). In conclusion, a rapid, reproducible, sensitive, and high-throughput HRMA assay has been established for the scanning of SF3B1 mutations.
  Genetic Testing and Molecular Biomarkers 02/2013; · 1.11 Impact Factor
• Article: SF3B1 mutation is a rare event in Chinese patients with acute and chronic myeloid leukemia.

  Jing Yang, Jun Qian, Dong-Ming Yao, Si-Xuan Qian, Wei Qian, Jiang Lin, Gao-Fei Xiao, Cui-Zhu Wang, Zhao-Qun Deng, Ji-Chun Ma, Xing-Xing Chen
  [show abstract] [hide abstract]
  ABSTRACT: OBJECTIVE: Somatic mutations of SF3B1 gene have recently been identified in myelodysplastic syndrome and chronic lymphocytic leukemia. The frequency and clinical relevance of SF3B1 mutations have been rarely studied in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). The present study was aimed to analyze the frequency of SF3B1 mutations in AML and CML. Designs and Methods High-resolution melting analysis (HRMA) was established to detect the mutation hotspots (codon E622, H662, K666, and K700) of SF3B1 gene in 275 AML and 81 CML patients. RESULTS: Heterozygous SF3B1 mutations were detected in three AML patients by HRMA. Direct DNA sequencing identified one K666T, one K666N and one K700E mutations. All three AML patients had normal karyotypes. One case also had NPM1 and DNMT3A mutations, one had FLT3 internal tandem duplication and DNMT3A mutations, and the other had NPM1 mutation. No SF3B1 mutations were detected in CML patients. CONCLUSIONS: SF3B1 mutation is a rare molecular event in Chinese AML and CML patients.
  Clinical biochemistry 02/2013; · 2.02 Impact Factor
• Article: RAS mutation analysis in 504 Chinese patients with acute myeloid leukemia.

  Xiaofei Yang, Jun Qian, Aining Sun, Jiang Lin, Gaofei Xiao, Jia Yin, Suning Chen, Depei Wu
  [show abstract] [hide abstract]
  ABSTRACT: OBJECTIVE: We examined RAS mutational status and correlated this with presenting morphology, cytogenetics, clinical outcome and other gene aberrations in a large cohort of Chinese acute myeloid leukemia (AML) patients. Designs and Methods N-RAS and K-RAS were screened for mutations at hot-spot codons 12, 13 and 61 using high resolution melting analysis (HRMA) and direct DNA sequencing in 504 Chinese AML patients and their clinical relevance was analyzed. RESULTS: The frequencies of mutations of N-RAS and K-RAS were 9.7% (49/504) and 2.9% (15/504), respectively. c.35G>A (rs121913237: G>A; p.Gly12Asp and rs121913529: G>A; p.Gly12Asp) and c.38G>A (rs121434596: G>A; p.Gly13Asp and rs112445441: G>A; p.Gly13Asp) were the most common base substitutions (46% in N-RAS and 60% in K-RAS, respectively). AML patients with RAS mutations presented significantly higher white blood cell count (WBC) at diagnosis than those without mutations (p<0.001). RAS mutations were underrepresented in patients with t(15;17) (2.9%, p=0.01), while overrepresented in cases with abn11q23 (50%, p=0.002) and inv(16) (66.6%, p=0.04). In the FAB subtypes M4 and M5, RAS mutations were more frequent (21.6% and 20.6%, respectively) than they were in other subtypes (7.5%, p=0.006 and 0.005, respectively). FLT3-ITD and RAS mutation were rarely coexistent (p=0.03). RAS mutation didn't influence overall survival (OS) either in the entire cohort or within some defined subgroups. CONCLUSIONS: RAS mutations are associated with some biologically specific subtypes of AML but don't impact clinical outcome in Chinese patients.
  Clinical biochemistry 01/2013; · 2.02 Impact Factor
• Article: [Expression of RAGE-1 Gene in Acute Myeloid Leukemia].

  Hai-Yan Chai, Jun Qian, Jiang Lin, Jing Yang, Yun Li, Cui-Zhu Wang, Xing-Xing Chen, Qin Chen, Zhao-Qun Deng, Dong-Ming Yao, Ji-Chun Ma
  [show abstract] [hide abstract]
  ABSTRACT: The purpose of this study was to detect the expression of RAGE-1 transcript in the bone marrow mononuclear cells (BMMNC) from patients with acute myeloid leukemia (AML) and to investigate the relationship of RAGE-1 expression level with clinical variables. The expression level of RAGE-1 gene in BMMNC from 94 newly diagnosed AML patients was measured using RQ-PCR. The relationship between RAGE-1 expression level and clinical parameters (age, sex, blood cell counts, diagnosis and prognosis) was investigated, and the levels of RAGE-1 expression were compared in patients before and after treatment. The results showed that overexpression of RAGE-1 transcript was found in 28% (26/94) AML patients (1.34 - 16.34, median 3.07). No significant difference was observed in sex, age, blood parameters and FAB subtypes between the groups with and without RAGE-1 overexpression. There was also no significant difference in the frequency of RAGE-1 overexpression among different cytogenetic risk groups and among the patients with different types of karyotypes. The level of RAGE-1 transcript significantly decreased in those patients obtained complete remission after treatment. The overall survival of AML patients with RAGE-1 overexpression was similar as that in those without RAGE-1 overexpression. It is concluded that RAGE-1 overexpression is a common event in AML, but has no impact on the prognosis of patients.
  Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology 01/2013; 21(1):20-4.
• Article: Aberrant hypomethylation of SALL4 gene is associated with intermediate and poor karyotypes in acute myeloid leukemia.

  Ji-Chun Ma, Jun Qian, Jiang Lin, Wei Qian, Jing Yang, Cui-Zhu Wang, Hai-Yan Chai, Yun Li, Qin Chen, Zhen Qian
  [show abstract] [hide abstract]
  ABSTRACT: OBJECTIVE: SALL4 gene has been identified to stimulate the expansion of hematopoietic stem cell (HSCs) and enhance the self-renewal of HSCs. Overexpression of SALL4 has been found in several cancers. The present study was aimed to investigate the methylation status of SALL4 promoter region in acute myeloid leukemia (AML). DESIGNS AND METHODS: The methylation status of SALL4 promoter was analyzed in 84 patients with AML using methylation-specific PCR (MSP) and its clinical significance was evaluated. RESULTS: Aberrant hypomethylation of SALL4 gene, which was correlated with SALL4 expression, was found in 17.8% (15/84) cases. The patients with SALL4 hypomethylation had significantly older age and higher WBCs than those without SALL4 hypomethylation. The incidence of SALL4 hypomethylation was higher in M1 subtype than in M2 and other subtypes (50%, 26% and 6%, respectively, P=0.001). SALL4 hypomethylation was associated with cytogenetically intermediate and poor groups. Although survival time of the SALL4-hypomethylated AML was shorter than that of SALL4-methylated group (4 months vs 9 months), the difference was not statistically significant (P= 0.356). CONCLUSIONS: Hypomethylation of SALL4 promoter is a common event and is associated with the intermediate and poor karyotypes in AML.
  Clinical biochemistry 11/2012; · 2.02 Impact Factor
• Article: Development of high-resolution melting analysis for the detection of the MYD88 L265P mutation.

  Cui-Zhu Wang, Jiang Lin, Jun Qian, Rui Shao, Di Xue, Wei Qian, Gao-Fei Xiao, Zhao-Qun Deng, Jing Yang, Yun Li, Xing-Xing Chen
  [show abstract] [hide abstract]
  ABSTRACT: OBJECTIVE: Recurrent L265P mutation of myeloid differentiation primary response gene 88 (MYD88) has been identified in a proportion of diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia. The present study was aimed to establish a rapid, sensitive, and reliable method using high-resolution melting analysis (HRMA) to detect MYD88 L265P mutation in DLBCL. DESIGNS AND METHODS: The sensitivity of HRMA in the detection of MYD88 L265P mutation was evaluated. MYD88 L265P mutation was further screened in 120 patients with DLBCL. The results of HRMA were validated by direct DNA sequencing. RESULTS: For the detection of MYD88 L265P mutation, the reproducible maximal sensitivity of HRMA was 5%, higher than that obtained by direct DNA sequencing (25%). Heterozygous MYD88 L265P mutations were identified in 11 (9.2%) DLBCL cases, all of which were diagnosed as non- germinal-center B cell (non-GCB) DLBCL. CONCLUSIONS: The HRMA assay is a rapid, sensitive, reliable, and high-throughput method to screen MYD88 L265P mutation and could be used in clinical diagnostic laboratories.
  Clinical biochemistry 11/2012; · 2.02 Impact Factor
• Article: Aberrant hypomethylation of SALL4 gene in patients with myelodysplastic syndrome.

  Jiang Lin, Jun Qian, Dong-Ming Yao, Wei Qian, Jing Yang, Cui-Zhu Wang, Hai-Yan Chai, Ji-Chun Ma, Zhao-Qun Deng, Yun Li, Qin Chen
  [show abstract] [hide abstract]
  ABSTRACT: The abnormalities of SALL4 gene, which encodes a zinc-finger transcription factor and is essential for developmental events, have been found to be involved in tumorigenesis. In this study, we investigated the methylation status of the CpG island of SALL4 promoter region in myelodysplastic syndrome (MDS) using methylation-specific PCR (MSP). Aberrant hypomethylation of SALL4 gene was found in 21.7% (18/83) of the cases analyzed. A significantly positive correlation was identified between the level of SALL4 transcript and the status of SALL4 hypomethylation (R=0.641, P<0.001). No correlation was found between SALL4 hypomethylation and clinical parameters. However, the frequency of SALL4 hypomethylation significantly increased in higher risk MDS (14% in Low/Int-1 versus 39% in Int-2/High, P=0.031). The association between SALL4 hypomethylation and the mutations in three methylation modifiers (IDH1, IDH2 and DNMT3A) was not observed. Although the estimated 50% survival time of the SALL4-hypomethylated group was shorter than that of SALL4-methylated group (11.0 months vs. 20.0 months), the difference was not statistically significant (P=0.430). These findings suggest that hypomethylation of SALL4 promoter is a common event in MDS.
  Leukemia research 10/2012; · 2.36 Impact Factor
• Article: Observation of Multiphoton-Induced Fluorescence from Graphene Oxide Nanoparticles and Applications in In Vivo Functional Bioimaging

  Jun Qian, Dan Wang, Fuhong Cai, Wang Xi, Li Peng, Zhenfeng Zhu, Hao He, Minglie Hu, Sailing He
  Angewandte Chemie International Edition 10/2012; 51(42):10570-10575. · 13.45 Impact Factor
• Article: Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia.

  Pei-Pei Xu, Bao-An Chen, Ji-Feng Feng, Lu Cheng, Guo-Hua Xia, Yu-Feng Li, Jun Qian, Jia-Hua Ding, Zu-Hong Lu, Xue-Mei Wang, Ke Xu, Margaret Schultz
  [show abstract] [hide abstract]
  ABSTRACT: The cytosine arabinoside (Ara-C)-based chemotherapy is the major remedial measure for acute myeloid leukemia (AML). Deoxycytidine kinase (DCK) and cytidine deaminase (CDA) are the key enzymes in the metabolism of Ara-C. Many single nucleotide polymorphisms (SNPs) and haplotypes of DCK and CDA, which contribute to susceptibility to Ara-C, have been identified in Africans and Europeans. However, there has been no report about the relation among three SNPs in DCK (rs115543896, rs72552079, and rs111454937) and two SNPs in CDA (rs2072671 and rs60369023), and their clinical response to Ara-C for a Chinese population. In this study, we aimed to investigate whether these five SNPs are associated with the therapeutic outcomes of Ara-C-based chemotherapy regimens in patients with AML. A total of 151 Chinese patients with AML were enrolled in our study. SNPs genotyping were performed using the MassARRAY system by means of the matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF-MS) method. The results illustrated that DCKrs111454937 AA genotype was more frequent in patients with higher platelet count, and A allele frequency was significantly higher in the group £40 years, lower white blood cell (WBC) count patients group and the group with platelet counts > 60'10(9)/L. Meanwhile, both DCKrs72552079 TC (OR = 1.225, 95%CI = 1.225 - 9.851, P = 0.0192) and CDArs60369023 GA (OR = 9.851, 95%CI = 1.31 - 77.93, P = 0.0263) significantly improved Ara-C-based chemotherapy response. While DCKrs11554389 AA (OR = 0.147, 95%CI = 0.027 - 0.801, P = 0.0267) was associated with the decrease of Ara-C-based chemotherapy response. It is evident that the DCK and CDA polymorphisms might be the important markers for the AML patients' therapy outcomes in a Chinese population.
  Chinese medical journal 06/2012; 125(12):2137-43. · 0.86 Impact Factor
• Article: Aberrant hypomethylation of DDX43 promoter in myelodysplastic syndrome.

  Qin Chen, Jiang Lin, Dong-ming Yao, Jun Qian, Wei Qian, Jing Yang, Hai-yan Chai, Ji-Chun Ma, Zhao-qun Deng, Cui-zhu Wang, Yun Li
  British Journal of Haematology 05/2012; 158(2):293-6. · 4.94 Impact Factor
• Article: IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.

  Jiang Lin, Dong-ming Yao, Jun Qian, Qin Chen, Wei Qian, Yun Li, Jing Yang, Cui-zhu Wang, Hai-yan Chai, Zhen Qian, Gao-fei Xiao, Wen-rong Xu
  [show abstract] [hide abstract]
  ABSTRACT: The somatic mutations of isocitrate dehydrogenase genes (IDH1 and IDH2) have been identified in a proportion of hematologic malignancies. We examined IDH1 R132 and IDH2 R140/R172 mutations by high resolution melting analysis and direct sequencing in Chinese patients with different myeloid malignancies including 198 acute myeloid leukemia (AML), 82 myelodysplastic syndrome (MDS), 85 chronic myeloid leukemia, and 57 myeloproliferative neoplasms. IDH1 and IDH2 mutations were found in four (2.0%) and ten (5.0%) AML and in two (2.4%) and three (3.6%) MDS cases, but not in other patients. IDH1 and IDH2 mutations were heterozygous and mutually exclusive. IDH1/2 mutations were significantly more frequently observed in cytogenetically normal AML or MDS compared to those without mutations. There was no difference in overall survival of both AML and MDS patients with or without IDH1/2 mutations (P = 0.177 and 0.407, respectively). In conclusion, IDH1/2 mutations are recurrent but rare molecular aberrations in Chinese AML and MDS.
  Annals of Hematology 04/2012; 91(4):519-25. · 2.62 Impact Factor
• Source

  Available from: arxiv.org

  Article: Observation of Multiphoton-induced Fluorescence from Nano Graphene Oxide and Its Applications in In vitro and In vivo Bioimaging

  Jun Qian, Dan Wang, Li Peng, Wang Xi, Fu-Hong Cai, Zhen-Feng Zhu, Hao He, Ming-Lie Hu, Sailing He
  [show abstract] [hide abstract]
  ABSTRACT: In the present paper, we observed both two-photon and three-photon induced distinct photoluminescence from GO nanoparticles under fs laser excitation. Conjugated with PEG molecules, GO nanoparticles exhibited high chemical stability, and could effectively label HeLa cells. Imaged with a two-photon scanning microscope, GO nanoparticles were observed to localize in the mitochondria, endoplasmic reticulum, Golgi and lysosome of HeLa cells. Furthermore, GO nanoparticles were micro-injected into the brain of a black mouse, and in vivo two-photon luminescence imaging illustrated that GO nanoparticles located at 300 {\mu}m depth in the brain could be clearly distinguished.
  02/2012;
• Article: U2AF1 Mutations in Chinese Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome.

  Jun Qian, Dong-Ming Yao, Jiang Lin, Wei Qian, Cui-Zhu Wang, Hai-Yan Chai, Jing Yang, Yun Li, Zhao-Qun Deng, Ji-Chun Ma, Xing-Xing Chen
  [show abstract] [hide abstract]
  ABSTRACT: Somatic mutations of U2AF1 gene have recently been identified in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). In this study, we analyzed the frequency and clinical impact of U2AF1 mutations in a cohort of 452 Chinese patients with myeloid neoplasms. Mutations in U2AF1 were found in 2.5% (7/275) of AML and 6.3% (6/96) of MDS patients, but in none of 81 CML. All mutations were heterozygous missense mutations affecting codon S34 or Q157. There was no significant association of U2AF1 mutation with blood parameters, FAB subtypes, karyotypes and other gene mutations in AML. The overall survival (OS) of AML patients with U2AF1 mutation (median 3 months) was shorter than those without mutation (median 7 months) (P = 0.035). No difference in the OS was observed between MDS patients with and without U2AF1 mutations. Our data show that U2AF1 mutation is a recurrent event at a low frequency in AML and MDS.
  PLoS ONE 01/2012; 7(9):e45760. · 4.09 Impact Factor
• Article: Monosomal Karyotypes among 1147 Chinese Patients with Acute Myeloid Leukemia: Prevalence, Features and Prognostic Impact.

  Xiao-Fei Yang, Ai-Ning Sun, Jia Yin, Cheng-Sen Cai, Xiao-Peng Tian, Jun Qian, Su-Ning Chen, De-Pei Wu
  [show abstract] [hide abstract]
  ABSTRACT: A monosomal karyotype (MK), defined as ≥2 autosomal monosomies or a single monosomy in the presence of additional structural abnormalities, was recently identified as an independent prognostic factor conveying an extremely poor prognosis in patients with acute myeloid leukemia (AML). In the present study, after excluding patients with t(15;17), t(8;21), inv(16) and normal karyotypes, 324 AML patients with cytogenetic abnormalities were the main subject of analysis. The incidences of MK were 13% in patients aged 15 to 60 years and 18% in those between 15 and 88 years old. MK was much more prevalent among elderly patients (p < 0.001) and was significantly associated with the presence of -7, -5, del(5q), abn12p, abn17p, -18 or 18q-, -20 or 20q- and CK (for all p <0.001 except for abn12p p=0.009), and +8 or +8q was less frequent in MK+ AML(p=0.007). No correlation was noted between monosomal karyotype and FAB subtype (p > 0.05); MK remained significantly associated with worse overall survival among patients with complex karyotype (p= 0.032); A single autosomal monosomy contributed an additional negative effect in OS of patients with structural cytogenetic abnormalities (P=0.008). This report presents the prevalence, feature and prognostic impact of MK among a large series of Chinese AML patients from a single center for the first time.
  Asian Pacific journal of cancer prevention: APJCP 01/2012; 13(11):5421-6. · 0.66 Impact Factor
• Article: Gene expression of helicase antigen in patients with acute and chronic myeloid leukemia.

  Qin Chen, Jiang Lin, Jun Qian, Dong-Ming Yao, Wei Qian, Yun Li, Hai-Yan Chai, Jing Yang, Cui-Zhu Wang, Ming Zhang, Gao-Fei Xiao
  [show abstract] [hide abstract]
  ABSTRACT: The aim of this study was to investigate the expression status of the helicase antigen (HAGE) transcript and its clinical significance in patients with acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). The expression of HAGE cDNA in bone marrow mononuclear cells from AML and CML patients was detected by using real-time quantitative PCR. The resuts indicated that overexpression of HAGE transcript (117.12% - 9842.70%, median 434.96%) was detected in 14.8% (11/74) AML patients. AML patients with HAGE cDNA expression were significantly older than those HAGE-negative patients (median 67 and 45 years, respectively, p = 0.001). HAGE cDNA expression was more frequently present among the patients with acute monoblastic leukemia (M(4) and M(5), 7 of 20, 35.0%), compared to the patients with acute non-monoblastic leukemia (M(1), M(2), M(3) and M(6), 4 of 54, 7.4%) (p = 0.007). 28.6% (8/28) cases with normal karyotypes showed HAGE cDNA overexpression, significantly higher than 7.5% (3 of 40) in those with chromosomal abnormalities (p = 0.041). Overexpression of HAGE transcript was found in 9 (34.6%) CML cases and more frequently observed at accelerated phase and blast crisis (4/4, 100%) than that at chronic phase (5/22, 22.7%) (p = 0.008). It is concluded that HAGE cDNA expression is relevant to specific subtypes of AML and to the progression of CML.
  Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology 10/2011; 19(5):1171-5.
• Article: [Detection of the IDH1 gene mutation in acute myeloid leukemia by PCR-high resolution melting analysis].

  Jiang Lin, Jun Qian, Dong-Ming Yao
  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 07/2011; 32(7):484-6.
• Article: Rapid and reliable detection of IDH1 R132 mutations in acute myeloid leukemia using high-resolution melting curve analysis.

  Jiang Lin, Jun Qian, Dong-Ming Yao, Yun Li, Jing Yang, Qin Chen, Hai-yan Chai, Gao-Fei Xiao, Wen-rong Xu
  [show abstract] [hide abstract]
  ABSTRACT: The mutations of isocitrate dehydrogenase 1 (IDH1) gene have been identified in a proportion of hematologic malignancies including acute myeloid leukemia (AML). The aim of the present study was to explore the reliability of the high-resolution melting analysis (HRMA) for the identification of IDH1 R132 mutations in AML. We evaluated the sensitivity of HRMA in the detection of IDH1 R132 mutation and screened IDH1 mutations in 110 AML patients using HRMA. The results of HRMA were validated by direct DNA sequencing. The reproducible sensitivity of HRMA was 5% for the detection of IDH1 R132 mutation, higher than 10% of direct DNA sequencing. Heterozygous IDH1 mutations were identified in 4 (3.6%) AML cases, which were R132H in 3 cases and R132S in 1 case confirmed by DNA sequencing. The HRMA is a rapid, accurate, reliable, high-throughput method to screen IDH1 gene mutations.
  Clinical biochemistry 07/2011; 44(10-11):779-83. · 2.02 Impact Factor